← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #543 OF 1,000 MOST-CITED

Labeling Control Records and Label Copies

FDA cited this observation 34 times across 34 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Drugs34
BY FISCAL YEAR
FY20252
FY20245
FY20231
FY20221
FY20211
FY20204
FY20199
FY20189
FY20172

How FDA worded it — real examples

The batch production and control records are deficient in that they do not include complete labeling control records of labeling.

RemedyRePack Inc. · Indiana, Pennsylvania · Drugs · 2025-04-14

The batch production and control records are deficient in that they do not include of labeling.

Kath Khemicals LLC · Macomb, Michigan · Drugs · 2025-04-03

The batch production and control records are deficient in that they do not include complete labeling control records, specimen and copy of labeling.

Neilmed Pharmaceuticals Inc · Santa Rosa, California · Drugs · 2024-05-08

The batch production and control records are deficient in that they do not include specimen of labeling.

LS Promotions Inc. · Ronkonkoma, New York · Drugs · 2024-05-02

The batch production and control records are deficient in that they do not include complete labeling control records, specimen and copy of labeling.

Qualgen, LLC · Edmond, Oklahoma · Drugs · 2024-03-19

The batch production and control records are deficient in that they do not include specimen of labeling.

Madcar Co Inc. · Islandia, New York · Drugs · 2023-12-20

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Pharma industry

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →